# ClinicalTrials.gov record NCT01436201

> PeptideScanner retained ClinicalTrials.gov record NCT01436201 at 2026-07-30T21:54:46.550Z. Its registry update date was 2014-10-07, and PeptideScanner's reviewed identity mapping was dulaglutide.

- Evidence object: `story:clinicaltrials-gov-nct01436201-dulaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-10-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01436201-dulaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct01436201-dulaglutide-v1.json
- Content SHA-256: `63b8f4551a9864ab67549412bdc4b9532d07fdfc48580336d36aaded3b980ec9`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT01436201 ([`ctg-observation-nct01436201-2014-10-07-32e2ed4a098a`](#source-ctg-observation-nct01436201-2014-10-07-32e2ed4a098a))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01436201 at 2026-07-30T21:54:46.550Z. Its registry update date was 2014-10-07, and PeptideScanner's reviewed identity mapping was dulaglutide. ([`ctg-observation-nct01436201-2014-10-07-32e2ed4a098a`](#source-ctg-observation-nct01436201-2014-10-07-32e2ed4a098a))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01436201 at 2026-07-30T21:54:46.550Z. Its registry update date was 2014-10-07, and PeptideScanner's reviewed identity mapping was dulaglutide. ([`ctg-observation-nct01436201-2014-10-07-32e2ed4a098a`](#source-ctg-observation-nct01436201-2014-10-07-32e2ed4a098a))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01436201-2014-10-07-32e2ed4a098a`](#source-ctg-observation-nct01436201-2014-10-07-32e2ed4a098a))

## Sources

<a id="source-ctg-observation-nct01436201-2014-10-07-32e2ed4a098a"></a>
- **ClinicalTrials.gov record NCT01436201 · retained source version 2014-10-07:32e2ed4a098ada98601f0ca1238466e05a565ef7e8c2bdf0dc4c0a681d2950ee** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01436201) (`ctg-observation-nct01436201-2014-10-07-32e2ed4a098a`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01436201." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct01436201-dulaglutide-v1.json SHA-256: 63b8f4551a9864ab67549412bdc4b9532d07fdfc48580336d36aaded3b980ec9.